Open Orphan (ORPH), the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services.
Is pleased to announce that the Company will be attending and presenting at a series of investor events from the 11th February to 26th March 2020.
Cathal Friel, Open Orphan’s Executive Chairman, or Trevor Phillips, CEO, will be in attendance for all the events and will be presenting an update to existing and potential investors on the Company’s acquisition of hVIVO and business plans for 2020. hVIVO, is a world leader in the provision of viral challenge studies, vaccine and viral laboratory services, supporting product development for customers developing antivirals, vaccines and respiratory therapeutics, all particularly relevant and topical in the environment of heightened awareness of the Coronavirus in 2020. It also has Europe’s only commercial 24 bed quarantine clinic and on-site virology laboratory at Queen Mary’s Hospital in London.
No new material information will be disclosed at any event.
A full schedule of the upcoming events is as follows:
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned